[1]Patent:WO2019/185882,2019,A1.Locationinpatent:Page/Pagecolumn59
[2]JournalofMedicinalChemistry,1963,vol.6,p.136-141
88620-29-5
89676-88-0
23863-20-9
511295-97-9 | 4-D-prolylmorpholine | AA00J2S4 | MFCD22407796
3202-35-5 | 4-(3-fluorophenoxy)piperidine | AA00J2WK | MFCD00035069
1094071-26-7 | (2-Methylpiperidin-2-yl)methanol | AA00J35W | MFCD14582623
1158319-46-0 | [2-(7-methyl-1H-benzimidazol-2-yl)ethyl]amine dihydrochloride | AA00J39H | MFCD13186336
1351615-13-8 | 4-(1H-Pyrazol-1-ylmethyl)piperidine dihydrochloride | AA00J3CX | MFCD16036183
1609407-09-1 | N-(5-bromo-2-methoxybenzyl)-2-(4-chlorophenyl)ethanamine hydrobromide | AA00J3G7 | MFCD13186383
1609403-69-1 | (2,5-difluorobenzyl)(4-methoxybenzyl)amine hydrobromide | AA00J3J4 | MFCD13186440
55654-81-4 | N-[2-(1H-indol-3-yl)ethyl]-2-propanamine hydrobromide | AA00J3LL | MFCD13186475
473444-31-4 | Dimethyl n-(4-iodobenzoyl)glutamate | AA00J3PC | MFCD01605810
1609402-76-7 | 3-(2-Bromophenoxy)-N-methylpropan-1-amine hydrochloride | AA00J3SC | MFCD26959500
